GERN - Geron Corporation
1.51 0.00 (0.00%)
After hours: 6:51PM EST
| Previous Close | 1.56 |
| Open | 1.60 |
| Bid | 1.52 x 1400 |
| Ask | 1.55 x 800 |
| Day's Range | 1.49 - 1.60 |
| 52 Week Range | 1.46 - 6.99 |
| Volume | 2,925,192 |
| Avg. Volume | 8,873,461 |
| Market Cap | 281.385M |
| Beta (3Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
Yahoo Finance Video•13 days agoMARKETS: Today's job numbers might have been too good and could spook stocks
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves as Wall Street digests headlines about US-China trade relations, this morning's BLS Employment Situation report, and a barrage of earnings, from Apple to Exxon Mobil. Here's the performance of recent earnings (as of 10:45 am EDT, Friday): ~Thurs AMC SBUX Starbucks Corp 10.60% SYMC(E) Symantec Corp 6.43% MET Metlife Inc 4.41% X U.S. Steel Corporation 2.54% WU Western Union Co (THE) -0.25% CBS CBS Corporation -1.25% EOG EOG Resources -2.25% AAPL Apple Inc -6.72% KHC The Kraft Heinz Company -7.82% GERN(HB) Geron Corp -8.11% SHAK Shake Shack Inc -11.41% GPRO GoPro Inc Cl A -21.80% OLED Universal Display Corp -27.13% WTW Weight Watchers Intl -29.87% ~Fri BMO CVX Chevron Corporation 3.48% STX(HB) Seagate Tech 2.78% IMGN Immunogen Inc 2.69% ABBV AbbVie Inc 2.48% XOM Exxon Mobil 1.41% DUK Duke Energy Corporation 0.58% BABA Alibaba Group Holding Ltd -0.84% CBOE CBOE Glbl Mkts Inc -1.23%
- ACCESSWIRE•12 hours ago
Healthcare Stocks with Turnaround Potential
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of GERN earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Geron Corp Earnings Call
- GlobeNewswire•7 days ago
Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif., Nov. 07, 2018 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to.
- ACCESSWIRE•9 days ago
Today's Research Reports on Trending Tickers: bluebird bio and Geron
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...
- Motley Fool•13 days ago
How Geron's Horrible Year Is a Great Reminder to Investors
Here are some lessons learned from a major setback that derailed its shares this year.
- Zacks•13 days ago
Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
- Zacks•13 days ago
Geron (GERN) Reports Q3 Loss, Misses Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 40.00% and -25.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
Geron: 3Q Earnings Snapshot
The Menlo Park, California-based company said it had a loss of 3 cents per share. The drugmaker posted revenue of $165,000 in the period. The company's shares closed at $1.85. A year ago, they were trading ...
- Motley Fool•13 days ago
Scary Markets, Frightening Stocks, and How to Keep From Panicking
Here's what you need to know to keep your cool in terrifying times.
- GlobeNewswire•13 days ago
Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American.
- Motley Fool•13 days ago
Why Geron Corporation Stock Is Ripping Higher Today
Geron's stock is on the rise today after the company announced two conference presentations for its lead clinical asset.
- GlobeNewswire•14 days ago
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced that clinical data related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be the subject of two oral presentations at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 1-4, 2018. The abstracts, summarizing clinical data from Part 1 of IMerge in myelodysplastic syndromes and the IMbark primary analysis in myelofibrosis, were published today on the ASH website at www.hematology.org.
- Zacks•17 days ago
What's in the Cards for Geron (GERN) This Earnings Season?
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
- ACCESSWIRE•17 days ago
Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...
- GlobeNewswire•21 days ago
Geron to Announce Third Quarter 2018 Financial Results on November 1, 2018
Geron Corporation (GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018. Geron will host a conference call to discuss the third quarter results and recent events at 4:30 p.m. ET the same day. Geron is a clinical stage biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
- GlobeNewswire•last month
Report: Developing Opportunities within CorEnergy Infrastructure Trust, Calumet Specialty Products Partners, Iron Mountain, Geron, Bruker, and Loews — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•last month
Geron (GERN) Stock Moves -0.58%: What You Should Know
In the latest trading session, Geron (GERN) closed at $1.72, marking a -0.58% move from the previous day.
- Motley Fool•last month
Here's Why Geron Plummeted 69% in September
The biotech's partner said goodbye. Investors cried.
- Zacks•last month
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
- Motley Fool•last month
Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?
A partner walks away and trial data fails to impress. Here's what's next for these biotech upstarts.
- Zacks•last month
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
- Benzinga•2 months ago
Benzinga's Bulls & Bears Of The Week: Apple, GE, IBM, Nike, Tesla And More
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included leaders in e-commerce, smartphones and footwear. Bearish calls included a struggling conglomerate ...
- Motley Fool•2 months ago
2 Stocks That Could Benefit Big From Geron's Stumble
A disappointing decision could mean one fewer competitor for these biotech companies.
